All Industry Workshops take place on Tuesday, Oct. 20 from 1:30-2:30pm. Instructions will be included on the Nexus 2020 Virtual platform.
Industry Workshops provide an opportunity for AMCP corporate members (commercial organizations) to showcase their latest drug therapies, technologies, and a wealth of products and services affecting professionals working in managed care pharmacy.*
Grab your lunch and join an Industry Workshop for the latest in cutting edge research and the latest in drug therapies.
Materials presented in workshops may be promotional and concentrate on a specific product, service, or therapeutic area. Therefore, these presentations are considered promotional and do not offer continuing education credit.
Basal Insulin Analogs– What Does it Mean for the Payer?
Sponsored by Sanofi
Health plans & PBMs are faced with navigating an increasing number of therapies to treat Type 2 diabetes, while challenged by therapeutic inertia and low rates of medication adherence by patients. These factors contribute to prolonged periods of hyperglycemia/hypoglycemia leading to increased risk of patients developing diabetes-related complications. This program will discuss the current guidelines for Type 2 Diabetes, appropriate treatment options, placement in therapy for newer basal insulin analogs, and review biosimilar interchangeability of basal insulins. The program will focus on the role of basal insulins in addressing the challenges facing clinicians and patients in achieving glucose control through real world data analysis.
Sean D. Sullivan, PhD Professor and Dean, University of Washington School of Pharmacy
Laura Wilson, PharmD- Outcomes Liaison Associate Director, General Medicines Division Sanofi
State of the Science in Oncology: The Era of Antibody Drug Conjugates
Sponsored by Seattle Genetics
In this wave of innovation in Oncology, antibody-drug conjugates (ADCs) continue to improve outcomes for patients with cancer. With the proven ADC technology platform leading the way of cutting-edge cancer research, improvements to the science and technology have led to increased development and approval of newer ADCs. Scientific advancements have also led to the potential of combining ADCs with treatments such as immunotherapy to further improve outcomes. This session will provide an overview of the evolving Oncology landscape, discuss the state of ADC technology, and highlight FDA-approved and novel ADCs on the horizon. Following the presentation, a panel comprised of diverse key decision makers in the US healthcare system will discuss their perspectives of ADCs and the value of targeted therapies in Oncology.
Vice President, Global Value, Access, and Pricing Seattle Genetics
Nilanjan Ghosh, MD, PhD
Chief, Lymphoma Division & Associate Director, Clinical Trials Levine Cancer Institute
Clinical Associate Professor of Medicine
Jeremy Whalen, PharmD, BCOP
Specialty Clinical Program Director, Oncology
Timothy Chiu, PharmD, BCPS
Pharmacist Evidence Analyst & Strategist – Oncology
Drug Intelligence and Strategy
* Industry Workshops may include preapproved information exchange content. Subject to federal laws and regulations, attendance at PIE sessions is restricted to payors, formulary committee, or other similar entity representatives with knowledge and expertise in the area of health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. For more information, visit our website.